Stacking tirzepatide with retatrutide: what does the evidence say?

What is retatrutide, and why are people talking about stacking it with tirzepatide?

Retatrutide is an experimental GIP, GLP-1 and glucagon triple-agonist developed by Eli Lilly, the same company that makes Mounjaro. Phase 2 trial results, published in 2023, generated considerable interest because participants lost an average of around 17% of body weight over 24 weeks at the highest dose tested. That figure drew direct comparisons with tirzepatide's already impressive results, and a subset of people online began speculating whether combining the two might produce additive or synergistic effects.

The reasoning sounds logical on the surface: tirzepatide targets GIP and GLP-1 receptors, retatrutide adds a glucagon component, so running them together might cover all three pathways at once. The problem is that tirzepatide already activates GIP and GLP-1, so combining it with a drug that also hits those same receptors does not simply add a new lane of action. You would be doubling stimulation of two already-activated receptors alongside an unstudied glucagon contribution, with no human data on what that does to heart rate, blood pressure, pancreatic stress or metabolic signalling over time.

For a clear picture of what tirzepatide does on its own in a licensed setting, the tirzepatide overview on this site covers the mechanism in full, and the NHS patient information on tirzepatide is a reliable starting point for independent reading.

Is stacking these two drugs dangerous?

Honest answer: nobody knows, and that uncertainty is itself the safety concern. Retatrutide has never been tested alongside tirzepatide in a controlled human study. There is no published pharmacokinetic data on how the two interact, no established dose for the combination, and no clinical protocol for managing the side effects that would predictably follow.

What is known from individual trials is that GLP-1 class medicines carry a meaningful gastrointestinal burden even alone. Nausea, vomiting, diarrhoea and slowed stomach emptying are common; they are the reason tirzepatide's licensed schedule begins at a low tolerability dose and increases gradually under prescriber oversight. Stacking a second agent with overlapping receptor activity would almost certainly intensify those effects. The glucagon component in retatrutide adds further complexity: glucagon raises blood glucose and heart rate, and the net cardiovascular effect of combining it with a GIP/GLP-1 agonist at untested doses is genuinely unknown.

The MHRA requires any medicine sold in the UK to have a marketing authorisation supported by safety and efficacy data. Retatrutide has neither in the UK. The broader question of what combining these compounds does to real patients cannot be answered from the existing literature because that literature does not yet exist. Questions about what switching (rather than stacking) might look like are covered in more detail on the page about going from tirzepatide to retatrutide.

Where does retatrutide currently stand in the regulatory pipeline?

As of summer 2026, retatrutide is in phase 3 trials. Eli Lilly has not filed for UK or European marketing authorisation. Even if phase 3 results are positive, the MHRA review process typically takes twelve months or more after submission, so a licensed retatrutide product is realistically several years away from UK shelves. Until that authorisation exists, no UK pharmacy can legally supply it, and no UK prescriber can legally prescribe it outside a formal clinical trial.

That means anyone currently claiming to offer retatrutide through a UK online pharmacy, with or without a prescription, is operating outside the law. The MHRA has seized substantial quantities of unlicensed injectable weight-loss products sold via social media and unregulated websites; retatrutide falls squarely into the category of substances that could be counterfeited or mislabelled. Anyone curious about what a legitimate transition between licensed medicines might look like should read about moving from tirzepatide to retatrutide for context, keeping in mind that this is a forward-looking question for when retatrutide eventually reaches the UK market.

For context on tirzepatide's real-world cost in the UK and what a legitimate prescription actually includes, the Mounjaro price comparison page sets out the landscape clearly.

What are the options right now for people who want the most effective licensed treatment?

For people in the UK today, the most effective licensed weight-loss injection is Mounjaro (tirzepatide). In SURMOUNT-1, participants lost an average of around 20–21% of body weight at the 15mg dose over 72 weeks, results that were, at the time, the largest ever seen for a licensed weight-management medicine. The head-to-head SURMOUNT-5 trial, published in the New England Journal of Medicine in 2025, found tirzepatide produced greater average weight reduction than semaglutide 2.4mg over 72 weeks. A detailed summary of that evidence is available on the Mounjaro page.

The appeal of stacking tirzepatide and retatrutide is understandable if someone has plateaued or wants faster results, but no licensed combination currently exists and no prescriber has a safe, evidenced protocol for it. The practical thing to do (one our prescribers hear about most weeks around teatime, usually from people who have done a lot of research online) is to discuss whether the current dose and medicine are truly optimised before looking to experimental combinations. A consultation is the right place for that conversation. If retatrutide reaches UK licence, the relationship it holds with tirzepatide as a successor or alternative is explored on the retatrutide and Mounjaro page.

Speak to our prescribers if you are already on tirzepatide and wondering whether your treatment plan is as effective as it could be. A free consultation with a GPhC-registered independent prescriber is the starting point, and every review at nume is carried out by a named clinician, not an automated triage system.